Clinical and immunological characteristics of patients with chronic hepatitis C during antiviral therapy in interferon-free regimen

Abstract

Aim. To study the biomarkers of liver inflammation that occur during antiviral therapy in the interferon-free regimen.

Methods. 14 patients were examined during antiviral therapy of chronic viral hepatitis C genotype 1. Treatment with dasabuvir, ombitasvir, paritaprevir and ritonavir for 12 weeks was received by 8 patients. Daklatasvir and asunaprevir was administered to 6 patients for 24 weeks. 11 patients had the concentrations of cytokines/chemokines (TNFα, CCL2/MCP-1, CCL20/MIP-3α, CXCL9/MIG, CXCL10/IP-10, CXCL11/ITAC) measured in the blood plasma by multiplex analysis. In six patients, the content of CXCR3+ and CCR6+ receptors in different subpopulations of lymphocytes was determined by flow cytofluorimetry. Patients were divided into 2 groups: without liver fibrosis and with severe fibrosis.

Results. 100% demonstrated virologic response. In both groups, significant reduction of CXCL10/IP-10 concentration was found in the patients at the end of treatment compared to pre-therapy (p=0.025 and 0.00015, respectively). In the first group a tendency to increase of the relative content of T-lymphocytes (p=0.065) was observed, and in the second group, a significant increase of the relative content of TNKCCR6+ (p=0.02) was observed.

Conclusion. Chemokine CXCL10/IP-10 is a biomarker characterizing the decrease of liver inflammation during therapy and not depending on the degree of liver fibrosis. The tendency to increase of the relative content of T lymphocytes in the first group and a significant increase in TNKCCR6+ cells during treatment in the second group may play an important role in eliminating hepatitis C virus.

Keywords

CXCL10/IP-10 / hepatitis C / antiviral therapy / interferon-free regimen / chemokines / CXCL10/IP-10 / fibrosis

References

[1] World Health Organization. Hepatitis C. Key facts. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c (access date: 18.06.18).

[2] Angeli P., Bernardi M., Villanueva C. et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of patients with decompensated cirrhosis. J. Hepatol. 2018; 69 (2): 406–460. DOI: 10.1016/j.jhep.2018.03.024.

[3] Angeli P., Bernardi M., Villanueva C. et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of patients with decompensated cirrhosis. J. Hepatol. 2018; 69 (2): 406-460. DOI: 10.1016/j.jhep.2018.03.024.

[4] Esaulenko E.V., Vysochinskaya V.V., Nikitina O.E. The effectiveness of combined antiviral therapy in patients with chronic hepatitis C, 1B genotype with various degrees of fibrosis. Zhurnal infektologii. 2012; 4 (3S): 75. (In Russ.)

[5] Эсауленко Е.В., Высочинская В.В., Никитина О.Е. Эффективность комбинированной противовирусной терапии у больных хроническим гепатитом С, 1В генотипом с различной степенью выраженности фиброза. Журнал инфектологии. 2012; 4 (3S): 75. DOI: 10.22625/2072-6732-2012-4-3S-7-120.

[6] Maevskaya M.V., Ivashkin V.T., Znojko O.O. at el. Efficacy and safety of the national inhibitor of Narlaprevir protease in primary and previously treated patients with chronic hepatitis C caused by the 1st genotype virus, without liver cirrhosis (results of the Pioneer study). Rossijskij zhurnal gastroehnterologii, gepatologii, koloproktologii. 2017; 27 (6): 41–51 (In Russ.)

[7] Маевская М.В., Ивашкин В.Т., Знойко О.О. и др. Эффективность и безопасность отечественного ингибитора протеазы Нарлапревира у первичных и ранее леченных пациентов с хроническим гепатитом С, вызванным вирусом 1-го генотипа, без цирроза печени (результаты исследования Pioneer). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (6): 41-51. DOI: 10.22416/1382-4376-2017-27-6-41-51.

[8] Ivashkin V.T., Maevskaya M.V., Аbdurakhmanov D.T. et al. Modern possibilities of antiviral therapy using Daclatasvir in the treatment of patients with chronic viral hepatitis C: results of the individual access program. Rossijskij zhurnal gastroehnterologii, gepatologii, koloprotologii. 2017; 27 (6): 52–62. (In Russ.)

[9] Ивашкин В.Т., Маевская М.В., Абдурахманов Д.Т. и др. Современные возможности противовирусной терапии с использованием Даклатасвира при лечении больных хроническим вирусным гепатитом С: Результаты программы индивидуального доступа. Российский журнал гастроэнтерологии, гепатологии, колопротологии. 2017; 27 (6): 52-62. DOI: 10.22416/1382-4376-2017-27-6-52-62.

[10] Lin J.C., Habersetzer F., Rodriguez-Torres M. et al. Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J. Infect. Dis. 2014; 210 (12): 881–885. DOI: 10.1093/infdis/jiu325.

[11] Lin J.C., Habersetzer F., Rodriguez-Torres M. et al. Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response. J. Infect. Dis. 2014; 210 (12): 881-885. DOI: 10.1093/infdis/jiu325.

[12] Bility M.T., Nio K., Li F. et al. Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation. Sci. Rep. 2016; (6): 39520. DOI: 10.1038/srep39520.

[13] Kazankov K., Barrera F., Moller H.J. et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014; 60 (2): 521–530. DOI: 10.1002/hep.27129.

[14] Kazankov K., Barrera F., Moller H.J. et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology. 2014; 60 (2): 521-530. DOI: 10.1002/hep.27129.

[15] Sandler N.G., Koh C., Roque A. et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011; 141 (4): 1220–1230. DOI: 10.1053/j.gastro.2011.06.063.

[16] Sandler N.G., Koh C., Roque A. et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011; 141 (4): 1220-1230. DOI: 10.1053/j.gastro.2011.06.063.

[17] Askarieh G., Alsio A., Pugnale P. et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010; 51: 1523–1530. DOI: 10.1002/hep.23509.

[18] Askarieh G., Alsio A., Pugnale P. et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010; 51: 1523-1530. DOI: 10.1002/hep.23509.

[19] Prinapori R., Sticchi L., Alicino C. et al. Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. Clin. Res. Hepatol. Gastroenterol. 2015; 39: 705–710. DOI: 10.1016/j.clinre.2015.04.001.

[20] Prinapori R., Sticchi L., Alicino C. et al. Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response. Clin. Res. Hepatol. Gastroenterol. 2015; 39: 705-710. DOI: 10.1016/j.clinre.2015.04.001.

[21] Mascia C., Vita S., Zuccalà P. et al. Changes in inflammatory biomarkers in HCV infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS ONE. 2017; 12 (6): e0179400. DOI: 10.1371/journal.pone.0179400.

[22] Serti E., Chepa-Lotrea X., Kim Y. J. et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015; 149 (1): 190–200. DOI: 10.1053/j.gastro.2015.03.004.

[23] Serti E., Chepa-Lotrea X., Kim Y. J. et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015; 149 (1): 190-200. DOI: 10.1053/j.gastro.2015.03.004.

[24] Diago C. M., Castellano G., GarcoAa-Samaniego J. et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis. Gut. 2006; 55 (3): 374–379. DOI: 10.1136/gut.2005.074062.

[25] Diago C. M., Castellano G., GarcoAa-Samaniego J. et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis. Gut. 2006; 55 (3): 374-379. DOI: 10.1136/gut.2005.074062.

RIGHTS & PERMISSIONS

Basina V.V., Sukhoruk A.A., Arsentieva N.A., Lyubimova N.E., Semenov A.V., Esaulenko E.V., Totolyan A.A.